Sanofi and bringer ingelham announced to sign the business exchange agreement and complete the transaction by the end of the year!

Source: on June 27, 2016, new ConocoPhillips announced the signing of business exchange agreement between Sanofi and Boehringer Ingelheim, including the exchange of Sanofi's animal health business ("Meria") and Boehringer Ingelheim's consumer health (CHC) business The deal is expected to close by the end of 2016 After that, Sanofi and Boehringer Ingelheim will respectively take the lead in the field of consumer health and animal health On June 27, Sanofi and bringer ingelham signed a business exchange agreement The Agreement deals with the exchange of Sanofi's animal health business ("Meria") with a valuation of EUR 11.4 billion and the consumer health (CHC) business of Boehringer Ingelheim with a valuation of EUR 6.7 billion For the price difference, Boehringer Ingelheim paid 4.7 billion euros in cash to Sanofi Boehringer Ingelheim's CHC business in China is not included in the deal It is learned from the six-month negotiation results that CHC business has not been running for a long time in China Some products are sold with prescription drugs and over-the-counter drugs at the same time, and CHC business in China market also includes Chinese patent medicines Considering these factors, this business exchange will exclude the Chinese market Boehringer Ingelheim said that before the signing of the agreement, the two sides carried out six months of constructive and successful negotiations as planned The two companies have reviewed and discussed the details of the deal This includes the specific scope of business swaps and ensuring compliance with regulatory requirements Through this transaction, Sanofi will integrate all the CHC businesses of Boehringer Ingelheim except for the Chinese market According to global sales data in 2015, combined CHC sales totaled approximately EUR 4.9 billion Similarly, Sanofi's Meria company will also merge with the existing products and technology businesses in such professional fields as antiparasitic, vaccine and pharmaceutical According to global sales data in 2015, the animal health business of Boehringer Ingelheim will double its sales to about 3.8 billion euros The deal, however, is still pending approval from regulators in different regions In the past few months, the two sides have held close consultations with relevant social institutions in France and Germany as well as relevant regulatory authorities, laying the foundation for the realization of business exchange, said Boehringer ingelham and Sanofi Behind the business exchange is the CHC sector Bringer Ingelheim consumer health is the eighth largest consumer health company in the world, with sales of EUR 1.51 billion in 2015, accounting for 10% of bringer Ingelheim's net sales Leading brands include the antispasmodic baishuping (2015 sales volume: 223 million euros), the cathartic lekeshu (2015 sales volume: 225 million euros), the cough medicine Mucosolvan (2015 sales volume: 168 million euros), etc The sales volume of Sanofi CHC business in 2015 is 3.4 billion euros, and the main brands include allergy products Allegra (sales volume in 2015 is 424 million euros), nasacort (sales volume in 2015 is 122 million euros), painkiller doliprane (sales volume in 2015 is 303 million euros), no Spa (sales volume in 2015 is 88 million euros), and dorflex (sales volume in 2015 is 81 million euros) Wait In animal health, Sanofi's Meria has three main business areas: pets, farm animals and veterinary public health, with sales of more than 2.5 billion euros in 2015 In 2015, the company achieved a net sales of about 1.36 billion euros, accounting for 9% of the total sales of 14.8 billion euros Considering the expected contribution of the acquisition of CHC business and other factors, Sanofi does not expect that the entire transaction will have an impact on the enterprise's EPS in 2017, and will have a value-added effect in the following years Andreas Barner, chairman of the Executive Board of Boehringer Ingelheim, said that as a research-based pharmaceutical company, Boehringer Ingelheim will significantly enhance its position in the future animal health market and may become one of the largest global players in this market segment Olivier brandicourt, CEO of Sanofi, said that the business exchange will bring a complementary combination of highly recognized brands to Sanofi's consumer health business, which can achieve medium-term and long-term value creation and improve Sanofi's market penetration in some major countries According to the commitment made by both parties at the beginning of the negotiation, Lyon and Toulouse, France, will become the main operation center of the animal health business of bringer Ingelheim, including the operation, R & D and manufacturing facilities in Lyon, as well as the production plant in Toulouse For Boehringer Ingelheim, as the U.S market is an important part of Meria's business, Boehringer Ingelheim will pay special attention to the development of the U.S business At the same time, Germany will become a key center of Sanofi's CHC business, especially for gastrointestinal and cough and cold classification products